Identification of drug candidates targeting monocyte reprogramming in people living with HIV
Name
fimmu-14-1275136.pdf
Description
Published version
Size
13.38 MB
Format
Adobe PDF
Checksum (MD5)
7cfb7f5e3938421498309e05e9b947a3
Author(s) • • • • • • • • •
Knoll, Rainer
Bonaguro, Lorenzo
dos Santos, Jéssica C
Warnat-Herresthal, Stefanie
Jacobs-Cleophas, Maartje CP
Blümel, Edda
Reusch, Nico
Horne, Arik
Herbert, Miriam
Nuesch-Germano, Melanie
Date Issued
November 19, 2023
Journal
Frontiers in Immunology
Publisher
Frontiers Media SA
Citation
Knoll R, Bonaguro L, dos Santos JC, Warnat-Herresthal S, Jacobs-Cleophas MCP, Blümel E, Reusch N, Horne A, Herbert M, Nuesch-Germano M, Otten T, van der Heijden WA, van de Wijer L, Shalek AK, Händler K, Becker M, Beyer MD, Netea MG, Joosten LAB, van der Ven AJAM, Schultze JL and Aschenbrenner AC (2023) Identification of drug candidates targeting monocyte reprogramming in people living with HIV. Front. Immunol. 14:1275136.
Version
Final published version
Abstract
Introduction: People living with HIV (PLHIV) are characterized by functional reprogramming of innate immune cells even after long-term antiretroviral therapy (ART). In order to assess technical feasibility of omics technologies for application to larger cohorts, we compared multiple omics data layers. Methods: Bulk and single-cell transcriptomics, flow cytometry, proteomics, chromatin landscape analysis by ATAC-seq as well as ex vivo drug stimulation were performed in a small number of blood samples derived from PLHIV and healthy controls from the 200-HIV cohort study. Results: Single-cell RNA-seq analysis revealed that most immune cells in peripheral blood of PLHIV are altered in their transcriptomes and that a specific functional monocyte state previously described in acute HIV infection is still existing in PLHIV while other monocyte cell states are only occurring acute infection. Further, a reverse transcriptome approach on a rather small number of PLHIV was sufficient to identify drug candidates for reversing the transcriptional phenotype of monocytes in PLHIV. Discussion: These scientific findings and technological advancements for clinical application of single-cell transcriptomics form the basis for the larger 2000-HIV multicenter cohort study on PLHIV, for which a combination of bulk and single-cell transcriptomics will be included as the leading technology to determine disease endotypes in PLHIV and to predict disease trajectories and outcomes.
MIT Department
Broad Institute of MIT and Harvard
Ragon Institute of MGH, MIT and Harvard
Massachusetts Institute of Technology. Department of Chemistry
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.3389/fimmu.2023.1275136